Clinical trials have investigated the use of IL-2 alone or in combination with other agents, such as checkpoint inhibitors, in treating various types of cancer, including melanoma and renal cell carcinoma. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.